White Bear Lake, Minnesota--(Newsfile Corp. - February 23, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the issuance of three new patents with one in the United States and two in Hong Kong, further expanding its intellectual property and reinforcing its competitive position in the cochlear implant industry.
"We believe the future of the cochlear implant industry is fully implanted devices and that our approach is novel when compared to other designs," said Brent Lucas, Chief Executive Officer of Envoy Medical. "As the industry realizes the wisdom and flexibility of our approach, we will have a strong patent portfolio to help protect our leadership position as a first mover with substantial differentiation."
Management believes that as the Company progresses toward potential Premarket Approval (PMA) submission and commercialization, the strength and breadth of its intellectual property portfolio will be an increasingly important asset, both strategically and competitively.
The United States Patent and Trademark Office granted U.S. Patent No. 12,544,564 on February 10, 2026, titled "Cochlear Implant System with Improved Input Signal-to-Noise Ratio." This patent relates to cochlear implant systems having a signal processor configured to filter a received input signal to attenuate a first pulse rate in the input signal and to output a stimulation signal based on the filtered input signal to cause a stimulator to provide electrical stimulation at the first pulse rate.
In addition, the Hong Kong Patent Office granted two complementary patents. Hong Kong Patent No. HK40102155, titled "Combination Hearing Aid and Cochlear Implant System." This patent relates to cochlear implant systems and receiving a status indicator signal indicative of whether an external auditory aid device (e.g., a hearing aid) is active and updating a transfer function of a signal processor of the cochlear implant system to compensate for operation of the external auditory aid device if it is active. This capability relates to the potential flexibility allowed by our system by leveraging the natural ear to pick up sound, which allows for (but does not require) the use of other devices in the ear.
Hong Kong Patent No. HK40107235, titled "Cochlear Implant System with Electrode Impedance Diagnostics," relates to impedance diagnostics within a cochlear implant system. This patent relates to impedance diagnostics in cochlear implant systems. A cochlear implant system can determine an impedance associated with a current path from a source element to a return electrode and determine one or more stimulation parameters for the source element based on the impedance. An example stimulation parameter can include a compliance voltage for the source element to provide a prescribed current.
The Acclaim® cochlear implant received Breakthrough Device Designation from the FDA in 2019 and is currently under investigation as part of a U.S. based pivotal clinical trial. For more information on the trial, visit www.envoymedical.com/acclaim-pivotal.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Click here for important information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.